NATCO Pharma peers

·Pharma & HealthChart ›

Companies like NATCO Pharmalatest year

NATCO PharmaNATCOPHARM · FY26 · this company
Market cap₹14,195
P/E10.01×
Sales growth−44.7%
ROE16.9%
Dr. Reddy's LaboratoriesDRREDDY · FY26
Open ›
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%
Zydus LifesciencesZYDUSLIFE · FY26
Open ›
Market cap₹1,18,255
P/E23.47×
Sales growth+22.0%
ROE19.7%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCOPHARM₹793.00

NATCO Pharma Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYZYDUSLIFESUNPHARMALALPATHLABNEULANDLABNHSAILIFECOHANCEMcap ₹14,195 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
NATCOPHARM
FY26
DRREDDY
FY26
ZYDUSLIFE
FY26
SUNPHARMA
FY26
Peer
Average
Valuation — at last close
P/E◆ 10.01×26.49×23.47×36.77×28.91× -65%
P/B◆ 1.54×2.94×4.36×5.05×4.12× -63%
EV/EBITDA◆ 8.89×17.19×14.78×22.19×18.06× -51%
Market Cap₹14,195 Cr₹1.12L Cr₹1.18L Cr₹4.22L Cr₹2.17L Cr -93%
Growth
Revenue CAGR 3Y14.64%10.96%◆ 16.35%10.03%12.45% +18%
Revenue CAGR 5Y◆ 14.72%12.09%12.45%11.78%12.11% +22%
Net Income CAGR 3Y25.64%-2.66%◆ 34.80%10.57%14.24% +80%
Revenue YoY (latest Q)-44.68%-1.48%◆ 21.96%10.46%10.31% -533%
Net Income YoY (latest Q)-57.01%-31.69%-34.90%◆ 26.53%-13.35% -327%
Profitability
EBITDA Margin◆ 35.22%19.15%31.22%30.33%26.90% +31%
Net Income Margin◆ 34.78%12.34%18.87%19.69%16.97% +105%
Return on Common Equity16.86%11.75%◆ 19.74%14.74%15.41% +9%
Return on Capital Employed14.40%11.30%◆ 21.79%18.48%17.19% -16%
Return on Assets◆ 14.40%7.73%11.44%11.46%10.21% +41%
Credit & Quality
Total Debt/Equity0.08×0.16×0.40×◆ 0.05×0.20× -61%
Interest Coverage33.51×11.76×16.10×◆ 43.65×23.84× +41%
Scale — latest FY
Revenue / Total Income₹4,078 Cr₹33,700 Cr₹27,148 Cr₹58,462 Cr₹39,770 Cr -90%
Net Income₹1,419 Cr₹4,158 Cr₹5,124 Cr₹11,509 Cr₹6,930 Cr -80%
Total Assets₹11,074 Cr₹58,123 Cr₹52,407 Cr₹1.09L Cr₹73,105 Cr -85%
EPS₹79.2₹50.41₹50.09₹47.8₹49.43 +60%
Book Value per Share₹515.15₹453.79₹269.5₹348.31₹357.2 +44%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.